Read More

Immunome To Acquire Antibody-Related Assets And Materials From Atreca; Under The Terms Of The Asset Purchase Agreement, Immunome Would Pay Atreca A $5.5M Upfront Payment And Up To $7M In Clinical Development Milestones

Immunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that it entered into a definitive asset purchase agreement with

BCEL